Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen

Blood

Volumn 88, Issue 1, 1996, Pages 41-48

  Cardoso, Angelo A ^a   Schultze, Joachim L ^b   Boussiotis, Vassiliki A ^b   Freeman, Gordon J ^b   Seamon, Mark J ^b   Laszlo, Susan ^b   Billet, Amy ^b   Sallan, Stephen E ^b   Gribben, John G ^b   Nadler, Lee M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; INTERLEUKIN 2 RECEPTOR; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LEUKEMIA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 8944238969     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.1.41.41     Document Type: Article

References (47)

1. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 169:1042, 1970
2. Schwartz RH, Mueller DL, Jenkins MK, Quill H: T-cell clonal anergy. Cold Spring Harb Symp Quant Biol 54:605, 1989
3. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173:721, 1991
4. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM: B7 provides a costimulatory signal which induces stimulated T cells to proliferate and secrete interleukin-2. Proc Natl Acad Sci USA 88:6575, 1991
5. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607, 1992
6. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo Jr. VA, Lombard LA, Gray GS, Nadler LM: Cloning of B7-2, a CTLA4 counter-receptor that costimulates human T cell proliferation. Science 262:909, 1993
7. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349, 1990
8. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM: The critical role of CD28 signaling in the prevention of human T-cell anergy. Res Immunol 146:140, 1995
9. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065, 1992
10. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islets grafts induced by CTLA4-Ig. Science 257:789, 1992
11. Gimmi CD, Freeman GJ, Gribben JG, Gray GS, Nadler LM: Human T cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90:6586, 1993
12. Boussiotis VA, Freeman GJ, Gray GS, Gribben JG, Nadler LM: B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 178:1753, 1993
13. Lin H, Boiling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4-Ig plus donor-specific transfusion. J Exp Med 178:1801, 1993
14. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 177:165, 1993
15. Boussiotis V, Freeman GJ, Griffin JD, Gray G, Gribben JG, Nadler LM: CD2 is involved in maintenance and reversal of human alloantigen specific clonal anergy. J Exp Med 180:1665, 1994
16. Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, D'Andrea AL, Ritz J, Nadler LM: Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor. Science 266:1039, 1994
17. Ostrand-Rosenberg S: Tumor immunotherapy: The tumor cell as antigen-presenting cell. Curr Opin Immunol 6:722, 1994
18. Dranoff G, Mulligan RC: Gene transfer as cancer therapy. Adv Immunol 58:417, 1995
19. Schultze JS, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM: Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92:8200, 1995
20. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093, 1992
21. + T cells by B7-transfected melanoma cells. Science 259:368, 1993
22. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher L: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated forms of major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:5687, 1993
23. Ramarathinam L, Castle M, Wu Y, Li Y: T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 179:1205, 1994
24. Hodges JW, Abrams S, Scholm J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552, 1994
25. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619, 1995
26. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD: Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507, 1995
27. Yang G, Hellstrom KE, Hellstrom I, Chen L: Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 154:2794, 1995
28. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD: B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 156:126, 1996
29. Townsend SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54:6477, 1994
30. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 79:523, 1994
31. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE: B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 54:5420, 1994
32. Urashima M, Chauhan H, Uchiyama H, Freeman GJ, Anderson KC: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85:1903, 1995
33. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 177:925, 1993
34. Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R: Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol 25:596, 1995
35. Poudrier J, Owens T: CD54/intracellular adhesion molecule 1 and major histocompatibility complex II signaling induces B cells to express interleukin 2 receptors and complements help provided through CD40 ligation. J Exp Med 179:1417, 1994
36. Teh HS, Phillips RA, Miller RG: Quantitative studies on the precursors of cytotoxic lymphocytes. II. Specificity of precursors responsive to alloantigens and to concanavalin A. J Immunol 118:1057, 1977
37. Corley RB: Responses of aloantigen-primed lymphocytes in vitro. Quantitative analysis of the relative frequency of reactive lymphocyts in primed populations which respond to allogeneic stimulating cells. Eur J Immunol 7:93, 1977
38. Van Oers MH, Pinkster J, Zeijlemaker WP: Quantification of antigen-reactive cells among human T lymphocytes. Eur J Immunol 8:477, 1978
39. Singal DP: Quantitative studies of alloantigen-reactive human lymphocytes in primary and secondary MLC. Hum Immunol 1:67, 1980
40. Jooss J, Zanker B, Wagner H, Kabelitz D: Quantitative assessment of interleukin-2-producing alloreactive human T cells by limiting dilution assays. J Immunol Meth 112:85, 1988
41. Breur-Vriesendorp BS, Vingerhoed J, Schaasberg WP, Ivanyi P: Variations in the T-cell repertoire against HLA antigens in humans. Hum Immunol 27:1, 1990
42. Gribben JG, Guinan EC, Boussiotis VA, Ke X-Y, Linsley L, Steff C, Gray GS, Freeman GJ, Nadler LM: Complete blockade of B7 mediated costimulation is necessary to induce human alloantigen specific anergy: a method to ameliorate graft versus host disease and extend the donor pool. Blood 87:4887, 1996
43. Orosz CG, Adams PW, Ferguson RM: Frequency of human alloantigen-reactive T lymphocytes. II. Method for limiting dilution analysis of alloantigen-reactive helper T cells in human peripheral blood. Transplantation 43:718, 1987
44. Harada M, Matsunaga K, Oguchi Y, Iijima H, Ito O, Tamada K, Kimura G, Nomoto K: The involvement of transforming growth factor beta in the impaired antitumor T-cell response at the gutassociated lymphoid tissue (GALT). Cancer Res 55:6146, 1995
45. Wilbanks GA, Mammolenti M, Streilein JW: Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol 22:165, 1992
46. Hara Y, Okamoto S, Rouse B, Streilein JW: Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of thr ocular type. J Immunol 151:5162, 1993
47. Okamoto S, Hara Y, Streilein JW: Induction of anterior chamber-associated immune deviation with lymphoreticular allogeneic cells. Transplantation 59:377, 1995